Plasma gastric inhibitory polypeptide and glucagon‐like peptide‐1 levels after glucose loading are associated with different factors in Japanese subjects

Aims/Introduction:  Gastric inhibitory polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) are major incretins that potentiate insulin secretion from pancreatic β‐cells. The factors responsible for incretin secretion have been reported in Caucasian subjects, but have not been thoroughly evaluated in Japanese subjects. We evaluated the factors associated with incretin secretion during oral glucose tolerance test (OGTT) in Japanese subjects with normal glucose tolerance (NGT).

[1]  D. Yabe,et al.  GIP and GLP‐1, the two incretin hormones: Similarities and differences , 2010, Journal of diabetes investigation.

[2]  Akihisa Imagawa,et al.  Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. , 2010, Biochemical and biophysical research communications.

[3]  Yutaka Seino,et al.  Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes. , 2010, Endocrine journal.

[4]  J. Holst,et al.  Little enhancement of meal‐induced glucagon‐like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls , 2010, Journal of diabetes investigation.

[5]  Yuichiro Yamada,et al.  Miglitol induces prolonged and enhanced glucagon‐like peptide‐1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[6]  D. Leroith,et al.  Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. , 2009, Endocrinology.

[7]  Yuichiro Yamada,et al.  Factors responsible for elevation of 1-h postchallenge plasma glucose levels in Japanese men. , 2008, Diabetes research and clinical practice.

[8]  Y. Seino,et al.  Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.

[9]  Andrea Mari,et al.  Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients , 2008, Diabetes.

[10]  O. Pedersen,et al.  Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action , 2008, Diabetologia.

[11]  Mark Ellrichmann,et al.  Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance , 2008, Diabetes.

[12]  P. Stein,et al.  Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.

[13]  J. Holst.  The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[14]  M. Namba,et al.  [Homeostasis model assessment as a clinical index of insulin resistance]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[15]  D. Drucker.  The biology of incretin hormones. , 2006, Cell metabolism.

[16]  Donald D Hensrud,et al.  Splanchnic lipolysis in human obesity. , 2004, The Journal of clinical investigation.

[17]  J. Ranstam,et al.  Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. , 2004, Diabetes care.

[18]  A. Mandavilli,et al.  News Feature: Asia's big problem , 2004, Nature Medicine.

[19]  Yuichiro Yamada,et al.  Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. , 2003, Diabetes care.

[20]  Yuichiro Yamada,et al.  Inhibition of gastric inhibitory polypeptide signaling prevents obesity , 2002, Nature Medicine.

[21]  L. Chuang,et al.  Comparison of measured and estimated indices of insulin sensitivity and beta cell function: impact of ethnicity on insulin sensitivity and beta cell function in glucose-tolerant and normotensive subjects. , 2001, The Journal of clinical endocrinology and metabolism.

[22]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[23]  J. Miyazaki,et al.  Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Tokuyama,et al.  Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. , 1999, Diabetes care.

[25]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[26]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[27]  J. Wishart,et al.  Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1 , 1998, Peptides.

[28]  J. Holst,et al.  The pathogenesis of NIDDM involves a defective expression of the GIP receptor , 1997, Diabetologia.

[29]  D. Kelley,et al.  Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.

[30]  R. DeFronzo,et al.  Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease , 1991, Diabetes Care.

[31]  P. Bennett,et al.  A two-step model for development of non-insulin-dependent diabetes. , 1991, The American journal of medicine.

[32]  S. Haffner,et al.  Increased insulin concentrations in nondiabetic offspring of diabetic parents. , 1988, The New England journal of medicine.

[33]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[34]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[35]  V. Marks,et al.  Abnormalities of GIP in Spontaneous Syndromes of Obesity and Diabetes in Mice , 1983, Diabetes.

[36]  Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance , 1979, Diabetes.

[37]  J. Brown,et al.  Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels , 1978, Diabetologia.

[38]  E. Imparato,et al.  Effect of quinestrol on plasma and urinary gonadotropins of postmenopausal women. , 1975, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[39]  M. T. Brennan,et al.  Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. , 1967, The Journal of clinical investigation.

[40]  K. Zierler,et al.  Forearm metabolism in obesity and its response to intra-arterial insulin. Characterization of insulin resistance and evidence for adaptive hyperinsulinism. , 1962, The Journal of clinical investigation.

[41]  Yuichiro Yamada,et al.  A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. , 2008, American journal of physiology. Endocrinology and metabolism.

[42]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[43]  Yuichiro Yamada,et al.  Factors responsible for deteriorating glucose tolerance in newly diagnosed type 2 diabetes in Japanese men. , 2006, Metabolism: clinical and experimental.

[44]  A. Mandavilli,et al.  Asia's big problem. , 2004, Nature medicine.

[45]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[46]  H. Imura,et al.  The Insulinogenic Index in Secondary Diabetes , 1975 .